Rania Zekry, Rehab H Werida, Ehab S Hegazy, Tarek M Mostafa
{"title":"Role of dexmedetomidine in brain injury: a systematic review.","authors":"Rania Zekry, Rehab H Werida, Ehab S Hegazy, Tarek M Mostafa","doi":"10.1007/s10787-025-01946-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Brain injuries are major health concern worldwide, that have debilitating effects on patients and affect patients' quality of life; therefore, we are in urgent need of identifying medications that have neuroprotective properties and help to maintain the patients' cognitive function. Dexmedetomidine is a sedative medication commonly used in ICU situations; recent studies show that it may have neuroprotective properties via different mechanisms.</p><p><strong>Aim: </strong>The aim of this article is to review available literature regarding the impact of using dexmedetomidine in various types of brain injury.</p><p><strong>Method: </strong>A systematic review of the published papers on the PubMed and google scholar that investigated the effects of dexmedetomidine on patients with different brain injuries was employed.</p><p><strong>Results: </strong>A total of 17 papers were included in this review, of which 1 was a case report, 6 were animal studies, 1 was a retrospective descriptive study, 2 were retrospective cohorts, 5 were randomized controlled trials, 1 was a scoping review, and 1 was a meta-analysis. These papers demonstrated the effects of dexmedetomidine on patients with traumatic brain injury, intracerebral hemorrhage, ischemic brain injury, status epilepticus, and on patients undergoing craniocerebral surgeries.</p><p><strong>Conclusion: </strong>Dexmedetomidine is a very promising drug to be used in different types of brain injuries and in craniocerebral surgeries because it has demonstrated impressive neuroprotective properties by a variety of mechanisms.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01946-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Brain injuries are major health concern worldwide, that have debilitating effects on patients and affect patients' quality of life; therefore, we are in urgent need of identifying medications that have neuroprotective properties and help to maintain the patients' cognitive function. Dexmedetomidine is a sedative medication commonly used in ICU situations; recent studies show that it may have neuroprotective properties via different mechanisms.
Aim: The aim of this article is to review available literature regarding the impact of using dexmedetomidine in various types of brain injury.
Method: A systematic review of the published papers on the PubMed and google scholar that investigated the effects of dexmedetomidine on patients with different brain injuries was employed.
Results: A total of 17 papers were included in this review, of which 1 was a case report, 6 were animal studies, 1 was a retrospective descriptive study, 2 were retrospective cohorts, 5 were randomized controlled trials, 1 was a scoping review, and 1 was a meta-analysis. These papers demonstrated the effects of dexmedetomidine on patients with traumatic brain injury, intracerebral hemorrhage, ischemic brain injury, status epilepticus, and on patients undergoing craniocerebral surgeries.
Conclusion: Dexmedetomidine is a very promising drug to be used in different types of brain injuries and in craniocerebral surgeries because it has demonstrated impressive neuroprotective properties by a variety of mechanisms.
期刊介绍：
Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas:
-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states
-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs
-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents
-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain
-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs
-Muscle-immune interactions during inflammation [...]
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
